In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 71, Issue SUPPL. 2, 2012, Pages

  Tanaka, Yoshiya ^a   Maeshima, Y ^a   Yamaoka, K ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; METHOTREXATE; PLACEBO; TOFACITINIB;

CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURFACE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; JAPANESE; LIGAND BINDING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZATION; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; SYNOVITIS; TH1 CELL; TH17 CELL; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; ISOENZYMES; JANUS KINASE 3; MICE; MICE, SCID; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION;

EID: 84859502626     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200595     Document Type: Conference Paper

References (19)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
2. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
3. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86.
4. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-8. (Pubitemid 37339629)
5. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-84.
6. Milici AJ, Kudlacz EM, Audoly L, et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008;10:R14.
7. D'Aura Swanson C, Paniagua RT, Lindstrom TM, et al. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat Rev Rheumatol 2009;5:317-24.
8. Johnston JA, Kawamura M, Kirken RA, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994;370:151-3. (Pubitemid 24229128)
9. Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol 2004;5:253.
10. Yamaoka K, Min B, Zhou YJ, et al. Jak3 negatively regulates dendritic-cell cytokine production and survival. Blood 2005;106:3227-33. (Pubitemid 41565923)
11. Yamaoka K, Maeshima K, Nakano K, et al. Involvement of Stat6 in inflammation by negatively regulating IL-10 production. Ann Rheum Dis 2010;69:333.
12. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-87.
13. Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev 2008;223:132-42. (Pubitemid 351986189)
14. Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006;65:149-56. (Pubitemid 43131986)
15. Maeshima K, Yamaoka K, Kubo S, et al. A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-γ and IL-17 production by human CD4+ T cells. Arthritis Rheum 2011. doi:10.1002/art.34329.
16. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905.
17. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010;69:413-16.
18. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63:1150-8.
19. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-19.